Business
Precipio Announces its Q1-2025 Financial Results
Conference call to follow tomorrow, May 15 at 5 PM ESTNEW HAVEN, Conn., May 14, 2025 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), filed its 10-Q report today. The following are the highlights of the Company’s financial performance and outlook for 2025. “We remain confident in the Company’s trajectory, supported by strong year-over-year revenue growth, improved gross margins, disciplined cost control and increasing operational efficiency”, said Ilan Dani
About this update from Precipio, Inc.
[{"type":"image","alt":"Precipio, Inc.","displaySize":"","headline":null,"caption":"Precipio, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":59,"url":"https://media.zenfs.com/en/globenewswire.com/ab6e80c50d815f9c4c3c5c7425f16fed"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/zOITnXM5v3wqbUHIrLobqQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTgzO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/ab6e80c50d815f9c4c3c5c7425f16fed","width":300,"height":59}},"lazy":false},{"type":"text","content":"Conference call to follow tomorrow, May 15 at 5 PM EST","length":54,"tagName":"p"},{"type":"text","content":"NEW HAVEN, Conn., May 14, 2025 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), filed its 10-Q report today. The following are the highlights of the Company’s financial performance and outlook for 2025.","length":251,"tagName":"p"},{"type":"text","content":"“We remain confident in the Company’s trajectory, supported by strong year-over-year revenue growth, improved gross margins, disciplined cost control and increasing operational efficiency”, said Ilan Danieli, Precipio’s CEO. “With our expectation of momentum building in our Product business pipeline, as well as the expanded reimbursement opportunities in Pathology Services, we anticipate continued revenue growth and a return to positive operating cash flow by Q2 or Q3. We believe 2025 will be a transformative year in which scalable growth translates into improved results and long-term shareholder value.”","length":611,"tagName":"p"},{"type":"text","content":"Q1-2025 Financial Results:","length":26,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Revenues. Q1-2025 revenues reached $4.9M, representing a 43% increase YoY. The quarter reported a decrease of 9.5% from Q4-2024 as a result of anticipated slower seasonal revenues in pathology and temporary delays in customer onboarding and operational ramp-up on the products side.","length":282,"tagName":"p"}]},{"val":[{"type":"text","content":"Adjusted EBITDA. Q1-2025 Adjusted EBITDA was ($108K) vs ($1,409K) YoY, a significant improvement of 92% resulting from both revenue growth and cost management initiatives.","length":171,"tagName":"p"}]},{"val":[{"type":"text","content":"Cash flow. Change in cash used in operations was ($44K) in Q1-2025 vs (...